IRWD
Ironwood Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.26
−0.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 389.3M | 296.2M | 351.4M | 442.7M | 410.6M |
| Cost of Revenue | 918.0K | — | 7.6M | 6.1M | 1.4M |
| Gross Profit | 388.4M | 296.2M | 343.9M | 436.6M | 409.2M |
| Operating Expenses | |||||
| R&D Expense | 87.8M | 95.1M | 111.4M | 116.1M | 44.3M |
| SG&A Expense | 64.5M | 82.3M | — | — | 116.0M |
| General & Admin Expense | 11.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 139.3M | 1.3B | (1.4M) |
| Total Operating Expenses | 152.3M | 177.4M | 250.7M | 1.4B | 158.8M |
| Cost and Expenses | 153.2M | 177.4M | 258.3M | 1.4B | 160.3M |
| Operating Income (EBIT) | 236.1M | 118.8M | 93.1M | (945.4M) | 250.3M |
| Non-Operating | |||||
| Interest Income | 5.7M | 4.1M | 4.5M | 19.0M | 9.5M |
| Interest Expense | 32.7M | 32.7M | 33.0M | 21.6M | 7.6M |
| Net Interest Income | (27.0M) | (28.7M) | (28.6M) | (2.7M) | 1.9M |
| Other Non-Op Income/Expense | (28.7M) | (48.7M) | (27.9M) | (2.6M) | 2.1M |
| Non-Operating Income (excl Interest) | (4.0M) | 16.0M | (2.6M) | (1.1B) | (9.7M) |
| EBT (Pre-Tax Income) | 207.4M | 70.0M | 65.2M | (948.1M) | 252.4M |
| Income Tax Expense | 77.5M | 46.0M | 64.3M | 83.5M | 77.4M |
| Bottom Line | |||||
| Net Income | 129.9M | 24.0M | 880.0K | (1.0B) | 175.1M |
| Earnings from Cont. Ops | 129.9M | 24.0M | 880.0K | (1.0B) | 175.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 128.5M | 24.0M | 880.0K | (1.0B) | 179.5M |
| Per Share | |||||
| Basic EPS | $0.80 | $0.15 | $0.01 | ($6.45) | $1.13 |
| Diluted EPS | $0.77 | $0.15 | $0.01 | ($6.45) | $0.96 |
| Revenue Per Share | $2.35 | $1.83 | $2.21 | $2.85 | $2.66 |
| Shares | |||||
| Basic Shares Outstanding | 165.5M | 162.2M | 159.1M | 155.4M | 154.4M |
| Diluted Shares Outstanding | 165.5M | 177.8M | 160.1M | 155.4M | 186.3M |
| Profitability Metrics | |||||
| EBITDA | 241.4M | 104.7M | 97.7M | 197.4M | 261.4M |
| D&A | 1.4M | 1.9M | 2.0M | 1.6M | 1.4M |
| EBIT | 240.0M | 102.8M | 95.7M | 195.8M | 260.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026